Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
STAT4 is expressed in neutrophils and promotes antimicrobial immunity
Pegah Mehrpouya-Bahrami, Alina K. Moriarty, Paulo De Melo, W. Coles Keeter, Nada S. Alakhras, Andrew S. Nelson, Madeline Hoover, Maria S. Barrios, Jerry L. Nadler, C. Henrique Serezani, Mark H. Kaplan, Elena V. Galkina
Pegah Mehrpouya-Bahrami, Alina K. Moriarty, Paulo De Melo, W. Coles Keeter, Nada S. Alakhras, Andrew S. Nelson, Madeline Hoover, Maria S. Barrios, Jerry L. Nadler, C. Henrique Serezani, Mark H. Kaplan, Elena V. Galkina
View: Text | PDF
Research Article Immunology

STAT4 is expressed in neutrophils and promotes antimicrobial immunity

  • Text
  • PDF
Abstract

Signal transducer and activator of transcription 4 (STAT4) is expressed in hematopoietic cells and plays a key role in the differentiation of T helper 1 cells. Although STAT4 is required for immunity to intracellular pathogens, the T cell–independent protective mechanisms of STAT4 are not clearly defined. In this report, we demonstrate that STAT4-deficient mice were acutely sensitive to methicillin-resistant Staphylococcus aureus (MRSA) infection. We show that STAT4 was expressed in neutrophils and activated by IL-12 via a JAK2-dependent pathway. We demonstrate that STAT4 was required for multiple neutrophil functions, including IL-12–induced ROS production, chemotaxis, and production of the neutrophil extracellular traps. Importantly, myeloid-specific and neutrophil-specific deletion of STAT4 resulted in enhanced susceptibility to MRSA, demonstrating the key role of STAT4 in the in vivo function of these cells. Thus, these studies identify STAT4 as an essential regulator of neutrophil functions and a component of innate immune responses in vivo.

Authors

Pegah Mehrpouya-Bahrami, Alina K. Moriarty, Paulo De Melo, W. Coles Keeter, Nada S. Alakhras, Andrew S. Nelson, Madeline Hoover, Maria S. Barrios, Jerry L. Nadler, C. Henrique Serezani, Mark H. Kaplan, Elena V. Galkina

×

Figure 4

IL-12 induces STAT4 activation in human neutrophils and supports neutrophil chemotaxis in vitro.

Options: View larger image (or click on image) Download as PowerPoint
IL-12 induces STAT4 activation in human neutrophils and supports neutrop...
(A and B) Human neutrophils were incubated with IL-12 (40 ng/mL) for indicated time points; stained for p-STAT4–PE, IL-12Rβ1 (FITC), and IL-12Rβ2 (Alexa Fluor 488); and analyzed by FACS. Representative histogram is shown (total: 4 donors in 2 independent experiments). (C) Isolated human neutrophils (0.5 × 106/200 μL in RPMI 1640+1% FBS) were either pretreated with IL-12 (40 ng/mL) or left untreated for 30 minutes and then seeded into Transwell inserts. Neutrophils migrated toward RPMI 1640 + 1% FBS media supplemented with 100 ng/mL recombinant human CXCL1 (rhCXCL1) or 50 ng/mL rGM-CSF, or migration media as a control, for 90 minutes at 37°C before being harvested and counted. The results depict neutrophil migration index normalized to the mean of the controls. *P < 0.05, **P < 0.01, ****P < 0.0001 using 1-way ANOVA followed by Tukey-Kramer post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts